Comparing two stem cell collection methods for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with multiple myeloma.
- Your doctor has decided a stem cell transplant (ASCT) is right for you.
- You are generally up and about (ECOG 0 or 1).
- Your heart, liver, and kidney function are good enough for the procedure.
- You haven't had stem cells collected before for a transplant.
- You must be free of active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to collect your own stem cells before a transplant in people with non-Hodgkin's lymphoma who are in remission. The goal is to see which method works better for getting enough healthy cells.
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
This study compares two treatments for newly diagnosed multiple myeloma: CAR-T cell therapy and a stem cell transplant. It aims to see which one works better for patients who are eligible for a stem cell transplant.
This trial compares two different chemotherapy drug combinations used before a stem cell transplant for multiple myeloma. The aim is to see if this new combination helps control the disease better before the transplant.
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.